Key findings of the report include
-The worldwide market for hormonal contraceptives is estimated at US$6.9bn in 2011, but is expected to decrease approximately 19.5% in annual revenues to US$5.5bn by 2018.
-Drivers of growth for the hormonal contraception sector will be novel transdermal and intravaginal products that offer greater efficacy, lower dosing, and improved and longer control over menstruation.
-Currently, there are over 40 pipeline candidates for female and male contraception.
-The current worldwide market for infertility drugs is US$2.5bn; however the infertility therapy sector is underserved with drugs that are mainly focused on female infertility that induce ovulation for assisted conception programs.
-Market leaders in the infertility sector include Merck Serono, Merck & Co., and Ferring with estimated revenues for their infertility products in 2011 at US$955m, US$625m and US$550m, respectively.
-Drivers of growth will be through innovation to: reduce side effects associated with pituitary-gonadal drugs; enhance qualitative and quantitative aspects of ovulation and spermatogenesis; and improve overall fertilization and pregnancy-birth rates.
-The male and female infertility R&D area is poorly served with only 15 pipeline candidates identified as potential clinical candidates.
Questions answered by this report include:
-Which contraceptives and infertility drugs are the current and potential future market leaders
-What impact new drug approvals will have on the reproductive medicine drug market
-Which premarket drugs are identified as high-value products
-Which companies are developing hormonal contraceptives and infertility drugs
-Sales predictions to 2018 for leading contraceptives and infertility dru
Copyright©2010 PR Newswire.
All rights reserved